リコンビナント
RabMAb

Anti-Tau (phospho S199) 抗体 [EPR2401Y] (ab81268)

製品の概要

  • 製品名
    Anti-Tau (phospho S199) antibody [EPR2401Y]
    Tau 一次抗体 製品一覧
  • 製品の詳細
    Rabbit monoclonal [EPR2401Y] to Tau (phospho S199)
  • 特異性
    ab81268 only detects Tau phosphorylated on Serine 199.
  • アプリケーション
    適用あり: WB, IHC-Frmore details
  • 種交差性
    交差種: Mouse, Rat, Human
  • 免疫原

    Synthetic phospho peptide (phospho S199) corresponding to residues surrounding Serine 199 of Human Tau.

  • ポジティブ・コントロール
    • WB: Mouse cerebral cortex and human hippocampus tissue lysates, SH SY5Y cell lysate.
  • 特記事項

    A trial size is available to purchase for this antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

製品の特性

関連製品

アプリケーション

Our Abpromise guarantee covers the use of ab81268 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB 1/5000 - 1/20000. Detects a band of approximately 55 kDa (predicted molecular weight: 79 kDa).
IHC-Fr Use at an assay dependent concentration. PubMed: 27861127

ターゲット情報

  • 機能
    Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
  • 組織特異性
    Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
  • 関連疾患
    Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
    Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
    Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
    Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
    Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
  • 配列類似性
    Contains 4 Tau/MAP repeats.
  • 発生段階
    Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
  • ドメイン
    The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
  • 翻訳後修飾
    Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
    Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
    Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
  • 細胞内局在
    Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
  • Information by UniProt
  • 参照データベース
  • 製品の状態
    There are 9 isoforms produced by alternative splicing.
  • 別名
    • AI413597 antibody
    • AW045860 antibody
    • DDPAC antibody
    • FLJ31424 antibody
    • FTDP 17 antibody
    • G protein beta1/gamma2 subunit interacting factor 1 antibody
    • MAPT antibody
    • MAPTL antibody
    • MGC134287 antibody
    • MGC138549 antibody
    • MGC156663 antibody
    • Microtubule associated protein tau antibody
    • Microtubule associated protein tau isoform 4 antibody
    • Microtubule-associated protein tau antibody
    • MSTD antibody
    • Mtapt antibody
    • MTBT1 antibody
    • MTBT2 antibody
    • Neurofibrillary tangle protein antibody
    • Paired helical filament tau antibody
    • Paired helical filament-tau antibody
    • PHF tau antibody
    • PHF-tau antibody
    • PPND antibody
    • PPP1R103 antibody
    • Protein phosphatase 1, regulatory subunit 103 antibody
    • pTau antibody
    • RNPTAU antibody
    • TAU antibody
    • TAU_HUMAN antibody
    • Tauopathy and respiratory failure, included antibody
    see all

画像

  • All lanes : Anti-Tau (phospho S199) antibody [EPR2401Y] (ab81268) at 1/1000 dilution

    Lane 1 : Mouse cerebral cortex tissue lysate
    Lane 2 : Mouse cerebral cortex tissue lysate. The membrane was incubated with phosphatase.

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Predicted band size : 79 kDa
    Observed band size : 55 kDa (why is the actual band size different from the predicted?)


    Exposure time : 5 seconds

    Blocking and dilution buffer: 5% NFDM/TBST.

  • All lanes : Anti-Tau (phospho S199) antibody [EPR2401Y] (ab81268) at 1/1000 dilution

    Lane 1 : Human hippocampus tissue lysate
    Lane 2 : Human hippocampus tissue lysate. The membrane was incubated with phosphatase.

    Lysates/proteins at 10 µg per lane.

    Secondary
    VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/2000 dilution

    Predicted band size : 79 kDa
    Observed band size : 55 kDa (why is the actual band size different from the predicted?)


    Exposure time : 1 minute

    Blocking and dilution buffer: 5% NFDM/TBST.

  • Dot blot analysis of Tau (pS199) peptide (Lane 1) and Tau non-phospho peptide (Lane 2) labelling Tau (pS199) with ab81268 at a dilution of 1/1000. ab97051 (peroxidase-conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/100000.

    Exposure time: 3 minutes.
    Blocking and dilution buffer: 5% NFDM/TBST.

  • All lanes : Anti-Tau (phospho S199) antibody [EPR2401Y] (ab81268) at 1/20000 dilution

    Lane 1 : SH SY5Y cell lysate
    Lane 2 : SH SY5Y cell lysate treated with alkaline phosphatase

    Lysates/proteins at 10 µg per lane.

    Secondary
    HRP labelled goat anti-rabbit at 1/2000 dilution

    Predicted band size : 79 kDa
    Observed band size : 55 kDa (why is the actual band size different from the predicted?)

参考文献

This product has been referenced in:
  • Yang SH  et al. Nec-1 alleviates cognitive impairment with reduction of Aß and tau abnormalities in APP/PS1 mice. EMBO Mol Med 9:61-77 (2017). WB, IHC ; Mouse . Read more (PubMed: 27861127) »
  • Jin WS  et al. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathol 134:207-220 (2017). Mouse . Read more (PubMed: 28477083) »

See all 4 Publications for this product

レビューと Q&A

Application
Western blot
Loading amount
10 µg
Gel Running Conditions
Reduced Denaturing (10)
Sample
Human Cell lysate - whole cell (human stem cell derived neurons (healthy/diseased))
Specification
human stem cell derived neurons (healthy/diseased)
Treatment
quinolinic acid 72h (and non treated)
Blocking step
BSA as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: rt°C
Username

Abcam user community

Verified customer

投稿 Mar 26 2014

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

登録